Source: http://radiotec.ru/article/13082
Timestamp: 2019-04-25 15:45:47+00:00

Document:
The review paper contains analysis of literature dedicated to various action modes of ASA, possibilities for using this preparation in treatment and prevention of ARMD, positive and negative effects of ASA administration. It has been experimentally proven  that ASA is capable of protecting brain cells from toxic and hypoxic hypoxia by inhibiting intracellular ATP reduction in hippocampus cells. ASA interferes with mitochondrial function, blocks glutamate receptors, reduces the level of mitogen-active kinases . Recovery of neuronal function after hypoxia goes on quicker after previous exposure of ASA. ASA is capable of decreasing the level of matrix metalloproteinases (ММР) in human endothelial cells, cultivated in a medium with high glucose content , which can neutralize complications connected with development of angiogenesis in diabetes. The review discusses the question of possibility of adverse side effects on retina in long-term administration of moderate and large doses of ASA. In particular, it was proven that in elderly patients ASA can provoke incidence of dry form of ARMD and its transformation into humid form . In patients with neovascular ARMD, a risk of subretinal hemorrhages, which redoubles at bilateral injury, increases in anti-platelet or anticoagulant therapy [9, 10, 15]. On the other hand, it was proven that ASA has a positive effect on ARMD course in combination, for example, with vitamin Е  or β-carotene [8, 19]. The analysis of literature allows assuming perspective character of administration of minimum effective doses of ASA (75 mg/day) in a short course of two months or less for treatment of dry form of ARMD, which would allow preventing hemorrhagic complications on the part of eyes and other organs, and on the other hand – preventing ASA adverse effects, associated with long-term administration of larger doses.
Domashenko M.A., Maksimova M.Ju., Tanashyan M.M. Aczetilsaliczilovaya kislota v lechenii i profilaktike czerebrovaskulyarny'x zabolevanij // Russkij mediczinskij zhurnal. 2011. № 30. S. 1930-1936.
Zueva M.V. Starenie setchatki: Chast' I. Degeneracziya i regress // Rossijskij oftal'mologicheskij zhurnal. 2010. T. 3. № 2. S. 53 – 61.
Zueva M.V. Starenie setchatki: Chast' II. Adaptivny'e proczessy' i plastichnost' // Rossijskij oftal'mologicheskij zhurnal. 2010. T. 3. № 3. S. 54 – 62.
Kiselyova T.N., Lagutina Ju.M., Kravchuk E.A., Gavrilenko A.V., Kuklin A.V., Dutikova E.F., Fateeva I.E. Osobennosti glaznogo krovotoka i sostoyaniya braxioczefal'ny'x arterij u bol'ny'x s nee'kssudativnoj vozrastnoj makulyarnoj degeneracziej // Vestnik oftal'mologii. 2006. № 4. S. 12 – 14.
Kiselyova T.N., Polunin G.S., Budzinskaya M.V., Lagutina Ju.M., Vorob'eva M.V. Sovremenny'e podxody' k lecheniyu i profilaktike vozrastnoj makulyarnoj degeneraczii // Klinicheskaya oftal'mologiya. 2007. № 2. S. 78 – 83.
Muxa A.I. Reologicheskie narusheniya krovi v patogeneze involyuczionnoj czentral'noj xorioretinal'noj distrofii i problema gemokomponentnoj terapii: Diss. … kand. med. nauk. M. 1999. 192 s.
Bonilha V.L. Age and disease-related structural changes in the retinal pigment epithelium // Clin. Ophthalmol. 2008. V. 2. № 2.
Christen W.G., Gaziano J.M., Hennekens C.H. Design of Physicians' Health Study II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials // Ann Epidemiol. 2000. V. 10. № 2. R. 125 – 134.
Kiernan D.F., Hariprasad S.M., Rusu I.M., Mehta S.V., Mieler W.F., Jager R.D. Epidemiology of the association between anticoagulants and intraocular hemorrhagein patients with neovascular age-related macular degeneration // Retina. 2010. V. 30. R. 1573 – 1578.
Kuhli-Hattenbach C, Fischer I.B., Schalnus R., Hattenbach L.O. Subretinal hemorrhages associated with age-related macular degeneration in patients receiving anticoagulation or antiplatelet herapy // Amer. J. Ophthalmol. 2010. V.149. R. 316 – 321.
Nicolae M., Tircol M., Alexandru D. Inhibitory effect of acetylsalicylic acid on matrix metalloproteinase – 2 activity in human endothelial cells exposed to high glucose // J. Cell. Mol. Med. 2005. V. 9. R. 953 – 960.
Paulus T.V.M., Chakravarthy U., Rahu M., Seland J., Soubrane G., Topouzis F., Vingerling J.R, Vioque J., Young I., Fletcher A.E. Associations between Aspirin Use and Aging Macula Disorder // European Eye Study. 2012. V. 119. R.112 – 118.
Riepe M.W., Kasischke K., Raupach A. Acetylsalicylic Acid Increases Tolerance Against Hypoxic and Chemical Hypoxia // Stroke. 1997. V. 28. R. 2006 – 2011.
The Anti–thrombotic Trialists Collaboration. Sollaborative meta–analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients // Brit. Med. J. 2002. V. 324. P. 71 – 86.
Tilanus M.A., Vaandrager W., Cuypers M.H., Verbeek A.M., Hoyng C.B. Relationship between anticoagulant medication and massive intraocular hemorrhage in age-related macular degeneration // Graefes Arch. Clin. Exp. Ophthalmol. 2000. V. 238. R.482 – 485.
Van Newkirk M. R., Nanjan M. B., Wang J. J. et al. The prevalence of age-related maculopathy. The visual impairment project // Ophthalmology. 2000. V. 107. №. 8. P. 1593 – 1600.
Vartiainen N., Goldsteins G., Keksa-Goldsteine V., Pak H., Chan, Koistinaho J. Aspirin Inhibits p44/42 Mitogen-Activated Protein Kinase and Is Protective Against Hypoxia/Reoxygenation Neuronal Damage // Stroke. 2003. V. 34. P. 752 – 757.
Christen W.G., Glynn R.J., Chew E.Y., Buring J.E. Low-Dose Aspirin and Medical Record Confirmed Age-related Macular Degeneration in a Randomized Trial of Women // Ophthalmology. 2009. V.116. R. 2386–2392.
Christen W.G., Glynn R.J., Ajani U.A., Schaumberg D.A., Chew E.Y., Buring J.E., Manson J.E., Hennekens Ch.H. Age-related maculopathy in a randomized trial of low-dose aspirin among US physicians // Arch Ophthalmol. 2001. V. 119. R. 1143 – 1149.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.